Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)
Frequently Asked Questions About Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)
Has Protalix entered any partnerships or collaborations?
Protalix BioTherapeutics has engaged in various collaborations and partnerships with other biopharmaceutical companies and research institutions to advance its product pipeline. These partnerships can help leverage complementary expertise, share resources, and expand the company's operational capabilities.
How can investors stay informed about Protalix?
Investors can stay informed about Protalix BioTherapeutics by regularly checking its official website, subscribing to press releases, and reviewing quarterly financial reports. Additionally, following industry news and analyst updates can provide insights into the company's performance and impact within the biopharmaceutical sector.
How does Protalix ensure product quality?
Protalix BioTherapeutics adheres to stringent quality control and assurance processes throughout its production and development stages. This includes compliance with Good Manufacturing Practices (GMP) and constant monitoring to ensure that its products meet the required safety and efficacy standards.
Is Protalix BioTherapeutics publicly traded?
Yes, Protalix BioTherapeutics is publicly traded on the New York Stock Exchange under the ticker symbol PLX. This allows investors to participate in the company's growth and potential success in the biopharmaceutical industry.
What are some challenges faced by Protalix?
Like many biopharmaceutical companies, Protalix BioTherapeutics faces multiple challenges, including competition in the biotech industry, regulatory hurdles, and the need for significant funding to support ongoing research and clinical trials. Successfully navigating these challenges is crucial for the advancement and commercialization of their products.
What are the company’s future prospects?
The future prospects for Protalix BioTherapeutics hinge on the successful development and commercialization of its product pipeline. With a focus on lysosomal storage disorders and leveraging its innovative ProCellEx® platform, the company aims to expand its therapeutic offerings and enhance its market presence.
What are the main products developed by Protalix?
Protalix BioTherapeutics has several products in its pipeline, including its lead product, Elelyso® (taliglucerase alfa), which is approved for the treatment of Gaucher disease. The company is also working on additional therapeutics targeting indications such as Fabry disease and other lysosomal storage disorders.
What does Protalix BioTherapeutics, Inc. do?
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of various diseases. Utilizing its proprietary ProCellEx® platform, the company specializes in producing therapeutic proteins that are made using genetically modified plant cells, providing advantages in terms of cost and efficiency.
What is Elelyso®?
Elelyso® (taliglucerase alfa) is a recombinant glucocerebrosidase enzyme replacement therapy developed by Protalix BioTherapeutics for the treatment of Gaucher disease. It was the first plant-cell produced therapeutic approved by the U.S. Food and Drug Administration (FDA), marking a significant milestone for the company.
What is Gaucher disease?
Gaucher disease is a genetic disorder caused by a deficiency of the enzyme glucocerebrosidase, which leads to the accumulation of harmful substances in certain organs. Patient symptoms can include enlargement of the liver and spleen, bone pain, and other systemic issues, making effective treatment crucial.
What is ProCellEx®?
ProCellEx® is Protalix BioTherapeutics' proprietary platform for producing therapeutic proteins using genetically modified plant cells. This technology allows for the production of complex proteins that can be used in the treatment of various diseases while minimizing costs and improving scalability in manufacturing.
What is the company's approach to R&D?
Protalix BioTherapeutics adopts a robust approach to research and development, focusing on innovation in protein production and therapeutic applications. The company emphasizes safety and efficacy through rigorous clinical testing and seeks to develop therapies that can significantly improve patient outcomes.
What is the financial status of Protalix?
Protalix BioTherapeutics' financial status can fluctuate based on factors such as research and development expenditures, revenue from product sales, and market conditions. Investors interested in the company should review quarterly financial reports and performance metrics to gain insight into its financial health.
What is the patient community's view on Protalix?
The patient community often views Protalix BioTherapeutics positively due to its focus on developing therapies for rare diseases like Gaucher disease. The company's commitment to addressing unmet medical needs resonates with patients and advocacy groups who seek reliable and effective treatments.
What regulatory approvals has Protalix received?
Protalix BioTherapeutics has received regulatory approvals for its lead product, Elelyso®, from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals signify the company's adherence to high safety and efficacy standards in its therapeutic offerings.
What social impact does Protalix aim to achieve?
Protalix BioTherapeutics aims to achieve a significant social impact by providing innovative treatments for rare diseases, ultimately improving patients' quality of life. By addressing unmet medical needs, the company contributes to advancements in healthcare and supports broader public health goals.
When was Protalix BioTherapeutics founded?
Protalix BioTherapeutics was founded in 1991. Since its inception, the company has focused on developing biopharmaceutical products using its unique plant-based expression system, which has set it apart in the biotechnology industry.
Where is Protalix BioTherapeutics located?
Protalix BioTherapeutics is headquartered in Carmiel, Israel. The company maintains facilities dedicated to research and development, manufacturing, and quality control, centralizing its operations for the advancement of its therapeutic products.
Who are the key executives at Protalix BioTherapeutics?
Protalix BioTherapeutics is led by a team of experienced executives, including the CEO and various other key positions responsible for driving the company's strategic direction, research and development, and operations. Key figures in management play an essential role in guiding the company's growth and product development.
What is the current price of Protalix BioTherapeutics, Inc. (DE) Common Stock?
The current price of Protalix BioTherapeutics, Inc. (DE) Common Stock is 2.590
When was Protalix BioTherapeutics, Inc. (DE) Common Stock last traded?
The last trade of Protalix BioTherapeutics, Inc. (DE) Common Stock was at 4:10 pm EDT on April 2nd, 2025
What is the market capitalization of Protalix BioTherapeutics, Inc. (DE) Common Stock?
The market capitalization of Protalix BioTherapeutics, Inc. (DE) Common Stock is 190.71M
How many shares of Protalix BioTherapeutics, Inc. (DE) Common Stock are outstanding?
Protalix BioTherapeutics, Inc. (DE) Common Stock has 73.63M shares outstanding.